BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/25/2021 10:52:18 AM | Browse: 415 | Download: 1097
 |
Received |
|
2020-09-26 02:49 |
|
Peer-Review Started |
|
2020-09-26 02:49 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-11-08 03:09 |
|
Revised |
|
2020-11-16 10:33 |
|
Second Decision |
|
2020-11-26 10:34 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-11-29 04:20 |
|
Articles in Press |
|
2020-11-29 04:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-12-18 07:13 |
|
Typeset the Manuscript |
|
2021-01-19 07:31 |
|
Publish the Manuscript Online |
|
2021-01-25 10:52 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu Zhang, Di Wu, Bo Zhao, Xue-Liang Tian, Tian-Cheng Yao, Feng Li, Wei-Fang Liu and Ai-Ping Shi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Health Specific Program of Jilin Province, China |
2018SCZWSZX-035 |
| Scientific and Technological Development Program of Jilin Province, China |
20190701041GH |
|
| Corresponding Author |
Ai-Ping Shi, MD, PhD, Professor, Department of Breast Surgery, The First Hospital of Jilin University, No. 71 Xinmin Street, Changchun 130021, Jilin Province, China. sap@jlu.edu.cn |
| Key Words |
Occult breast cancer; Neoadjuvant chemotherapy; Anlotinib; Mastectomy; Pathological complete response; Case report |
| Core Tip |
Occult breast cancer (OBC) is a rare type of breast cancer and there are some difficulties and confusion in its diagnosis and treatment. Biopsy and immunohistochemical analysis can help to make a diagnosis after excluding the possibility of other primary cancers. Because of its low incidence, there is no systematic and standard treatment plan. We first reported the application of neoadjuvant chemotherapy combined with anlotinib in OBC, and pathologic complete response was obtained after operation. This case may provide a new, suitable treatment option for these patients. |
| Publish Date |
2021-01-25 10:52 |
| Citation |
Zhang Y, Wu D, Zhao B, Tian XL, Yao TC, Li F, Liu WF, Shi AP. Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature. World J Clin Cases 2021; 9(4): 919-926 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i4/919.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i4.919 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
